Peter M. Dibattiste

Pete co-founded Prolocor and has served as the company's CEO since 2020. Prior to founding Prolocor, he spent 14 years in a cardiovascular leadership role with Janssen R&D, most recently as Global Development Head of Cardiovascular and Head of Thrombosis Disease Area Stronghold. At Janssen, Pete oversaw numerous early and late-stage cardiovascular development programs, heading a group of 35 physicians and

Scientists specializing in cardiovasCular drug development. Earlier in his career, Pete was a member of cardiovascular research and development

groups at AstražZeneca and Merck. Prior to joining the industry, Pete practiced medicine and was an Adjunct Professor at the University of Pennsylvania School of Medicine, The Lankenau Hospital, and Hahnemann University Hospital. He has authored more than 40

peer-reviewed publications in cardiovascular medicine. Pete completed his Fellowship in Cardiology at the University of Pennsylvania. He holds an

MD from Harvard Medical School.